Aleksandar Denic1, Marija Bogojevic1, Aidan F Mullan2, Moldovan Sabov1, Muhammad S Asghar1, Sanjeev Sethi3, Maxwell L Smith4, Fernando C Fervenza1, Richard J Glassock5, Musab S Hommos6, Andrew D Rule7,8. 1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. 2. Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota. 3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona. 5. Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, California. 6. Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, Arizona. 7. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota rule.andrew@mayo.edu. 8. Division of Epidemiology, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Semiquantitative visual inspection for glomerulosclerosis, interstitial fibrosis, and arteriosclerosis is often used to assess chronic changes in native kidney biopsies. Morphometric evaluation of these and other chronic changes may improve the prognostic assessment. METHODS: We studied a historical cohort of patients who underwent a native kidney biopsy between 1993 and 2015 and were followed through 2021 for ESKD and for progressive CKD (defined as experiencing 50% eGFR decline, temporary dialysis, or ESKD). Pathologist scores for the percentages of globally sclerosed glomeruli (GSG), interstitial fibrosis and tubular atrophy (IFTA), and arteriosclerosis (luminal stenosis) were available. We scanned biopsy sections into high-resolution images to trace microstructures. Morphometry measures were percentage of GSG; percentage of glomerulosclerosis (percentage of GSG, ischemic-appearing glomeruli, or segmentally sclerosed glomeruli); percentage of IFTA; IFTA foci density; percentage of artery luminal stenosis; arteriolar hyalinosis counts; and measures of nephron size. Models assessed risk of ESKD or progressive CKD with biopsy measures adjusted for age, hypertension, diabetes, body mass index, eGFR, and proteinuria. RESULTS: Of 353 patients (followed for a median 7.5 years), 75 developed ESKD and 139 experienced progressive CKD events. Visually estimated scores by pathologists versus morphometry measures for percentages of GSG, IFTA, and luminal stenosis did not substantively differ in predicting outcomes. However, adding percentage of glomerulosclerosis, IFTA foci density, and arteriolar hyalinosis improved outcome prediction. A 10-point score using percentage of glomerulosclerosis, percentage of IFTA, IFTA foci density, and any arteriolar hyalinosis outperformed a 10-point score based on percentages of GSG, IFTA, and luminal stenosis >50% in discriminating risk of ESKD or progressive CKD. CONCLUSION: Morphometric characterization of glomerulosclerosis, IFTA, and arteriolar hyalinosis on kidney biopsy improves prediction of long-term kidney outcomes.
BACKGROUND: Semiquantitative visual inspection for glomerulosclerosis, interstitial fibrosis, and arteriosclerosis is often used to assess chronic changes in native kidney biopsies. Morphometric evaluation of these and other chronic changes may improve the prognostic assessment. METHODS: We studied a historical cohort of patients who underwent a native kidney biopsy between 1993 and 2015 and were followed through 2021 for ESKD and for progressive CKD (defined as experiencing 50% eGFR decline, temporary dialysis, or ESKD). Pathologist scores for the percentages of globally sclerosed glomeruli (GSG), interstitial fibrosis and tubular atrophy (IFTA), and arteriosclerosis (luminal stenosis) were available. We scanned biopsy sections into high-resolution images to trace microstructures. Morphometry measures were percentage of GSG; percentage of glomerulosclerosis (percentage of GSG, ischemic-appearing glomeruli, or segmentally sclerosed glomeruli); percentage of IFTA; IFTA foci density; percentage of artery luminal stenosis; arteriolar hyalinosis counts; and measures of nephron size. Models assessed risk of ESKD or progressive CKD with biopsy measures adjusted for age, hypertension, diabetes, body mass index, eGFR, and proteinuria. RESULTS: Of 353 patients (followed for a median 7.5 years), 75 developed ESKD and 139 experienced progressive CKD events. Visually estimated scores by pathologists versus morphometry measures for percentages of GSG, IFTA, and luminal stenosis did not substantively differ in predicting outcomes. However, adding percentage of glomerulosclerosis, IFTA foci density, and arteriolar hyalinosis improved outcome prediction. A 10-point score using percentage of glomerulosclerosis, percentage of IFTA, IFTA foci density, and any arteriolar hyalinosis outperformed a 10-point score based on percentages of GSG, IFTA, and luminal stenosis >50% in discriminating risk of ESKD or progressive CKD. CONCLUSION: Morphometric characterization of glomerulosclerosis, IFTA, and arteriolar hyalinosis on kidney biopsy improves prediction of long-term kidney outcomes.
Authors: E Wazna; J Pazik; A Perkowska-Ptasińska; Z Lewandowski; S Nazarewski; A Chmura; M Durlik Journal: Transplant Proc Date: 2009-10 Impact factor: 1.066
Authors: Amy K Mottl; Adil Gasim; Fernanda Payan Schober; Yichun Hu; Askia K Dunnon; Susan L Hogan; J Charles Jennette Journal: J Am Soc Nephrol Date: 2017-11-27 Impact factor: 10.121
Authors: Musab S Hommos; Caihong Zeng; Zhihong Liu; Jonathan P Troost; Avi Z Rosenberg; Matthew Palmer; Walter K Kremers; Lynn D Cornell; Fernando C Fervenza; Laura Barisoni; Andrew D Rule Journal: Kidney Int Date: 2017-12-19 Impact factor: 10.612
Authors: Valerie A Luyckx; Andrew D Rule; Katherine R Tuttle; Pierre Delanaye; Helen Liapis; Afschin Gandjour; Paola Romagnani; Hans-Joachim Anders Journal: Nat Rev Nephrol Date: 2021-12-08 Impact factor: 42.439
Authors: Michael T Eadon; Tae-Hwi Schwantes-An; Carrie L Phillips; Anna R Roberts; Colin V Greene; Ayman Hallab; Kyle J Hart; Sarah N Lipp; Claudio Perez-Ledezma; Khawaja O Omar; Katherine J Kelly; Sharon M Moe; Pierre C Dagher; Tarek M El-Achkar; Ranjani N Moorthi Journal: Am J Kidney Dis Date: 2020-04-24 Impact factor: 8.860
Authors: Anand Srivastava; Ragnar Palsson; Arnaud D Kaze; Margaret E Chen; Polly Palacios; Venkata Sabbisetti; Rebecca A Betensky; Theodore I Steinman; Ravi I Thadhani; Gearoid M McMahon; Isaac E Stillman; Helmut G Rennke; Sushrut S Waikar Journal: J Am Soc Nephrol Date: 2018-06-04 Impact factor: 10.121
Authors: Sharon L Ford; Kevan R Polkinghorne; Anthony Longano; John Dowling; Sukhpal Dayan; Peter G Kerr; Stephen R Holdsworth; A Richard Kitching; Shaun A Summers Journal: Am J Kidney Dis Date: 2013-10-30 Impact factor: 8.860
Authors: Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton Journal: Mayo Clin Proc Date: 2012-11-28 Impact factor: 7.616